跳至主要内容
临床试验/EUCTR2015-005356-99-PL
EUCTR2015-005356-99-PL进行中(未招募)1 期

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes - PRONTO-T1D

Eli Lilly and Company0 个研究点目标入组 1,392 人开始时间: 2017年5月19日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,392

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • You were diagnosed with type 1 diabetes at least one year ago.
  • You are 18 years old or older.
  • You are already using a long-acting insulin and rapid-acting insulin analog.
  • Your blood glucose levels are within allowed limits for study participation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1175
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 392

排除标准

  • You have had more than 1 emergency treatment for very low blood glucose in the last 6 months.
  • You have had more than 1 emergency treatment for poor glucose control in the last 6 months.
  • You are taking certain diabetes medications that are not allowed for study participation.
  • You have major problems with your heart, kidneys, liver, or you have a blood disorder.
  • You have had or are now being treated for certain types of cancer that prevents you from study participation.

研究者

相似试验

进行中(未招募)
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 20.1Level: LLTClassification code 10020639Term: HyperglycemiaSystem Organ Class: 100000004861Type 1 Diabetes
EUCTR2015-005356-99-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER1,392
进行中(未招募)
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.Type 1 Diabetes
EUCTR2015-005356-99-GREli Lilly and Company1,199
进行中(未招募)
不适用
A Prospective, Randomized, Double-Blind Comparisonof a Long-Acting Basal Insulin Analog LY2963016 toLantus® in Adult Patients with Type 2 Diabetes Mellitus - The ELEMENT 2 Studytype 2 diabetes mellitusMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2011-000828-15-DEEli Lilly and Company792
进行中(未招募)
1 期
A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetesDiabetes Mellitus, Type 1
EUCTR2017-003399-30-ATEli Lilly and Company632
进行中(未招募)
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 19.1 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861Type 1 Diabetes
EUCTR2015-005356-99-ESilly S.A.1,328